Core Viewpoint - Creatd, Inc. is advancing its uplisting process by preparing to file its 2025 audited financials and re-register with the SEC, following a period of trading above $4.00 for 30 consecutive days [2] Group 1: Shareholder Meeting - The record date for the upcoming annual shareholder meeting is set for April 17, 2026, with the virtual meeting scheduled for May 21, 2026 [1] - Shareholders of record will be entitled to notice of and to vote at the virtual annual meeting, which will address strategic initiatives, governance matters, and future direction [2] Group 2: Company Operations - Creatd, Inc. focuses on acquiring, building, and scaling technology-driven businesses within a diversified portfolio, utilizing a shared services platform to enhance growth and monetization [3]

Core Insights - JETOUR Auto is conducting extreme testing of its T1 model in the Atacama Desert, emphasizing the need for real-world durability and reliability in off-road vehicles [1][3] Testing Environment - The Atacama Desert is characterized by extreme conditions, including low humidity (as low as 5%), high temperatures, corrosive dust, and a record of no measurable rainfall for 91 years [3] - The desert's daily temperature fluctuations exceed 30°C, making it a challenging environment for vehicle performance [3] Off-Road Recovery Test - The JETOUR T1 faced 30-centimeter-deep sand pits in the Atacama Desert, testing its off-road capabilities [5] - The vehicle's XWD intelligent all-wheel drive system activates Sand Mode to navigate the loose, quicksand-like terrain, achieving an instantaneous peak torque of 390 N·m [6] Handling Test - The T1 was tested on a low-friction crystalline surface formed by morning frost and salt-alkali deposits, which significantly reduces tire grip [7] - The XWD system allows for real-time responsiveness and seamless switching between 2WD and 4WD modes, maintaining stability even at high speeds [8] Seal Integrity Test - The T1's cabin sealing performance was tested against high-concentration fine dust, achieving over 95% filtration efficiency against PM2.5 particles [10] - After one hour of driving in desert dust, the interior remained virtually dust-free, with PM2.5 levels controlled below 35 [11] Climbing Test - The T1 demonstrated its capability on 30° weathered slopes, with a 28° approach angle and 29° departure angle, showcasing its 200 mm ground clearance [12] - The vehicle's 2.0T turbocharged engine maintained a steady output of 187 kW, effectively managing the extreme environmental challenges [12] Commitment to Safety and Reliability - JETOUR Auto's testing philosophy focuses on exploring extreme environments, reinforcing its commitment to user safety and reliability in all-terrain travel [13]

Core Insights - 20/20 BioLabs, Inc. has received over $520,000 in funding from the Maryland Department of Health to support the procurement and administration of its OneTest™ multi-cancer early detection blood test for firefighters [1][2] Funding and Program Details - The funding is part of the Professional and Volunteer Firefighter Innovative Cancer Screening Technologies Grant Program, with testing expected to exceed 1,400 firefighters in April or May 2026, representing a ~225% increase in funding compared to the previous year [2] - The Salisbury Fire Department has successfully conducted nearly 300 screenings over the past three years using the OneTest, highlighting the efficiency and satisfaction with the product and service [3] Market and Legislative Context - Maryland is among several states establishing dedicated funding for firefighters to access multi-cancer early detection testing, with more states anticipated to follow suit in the next 24 months [3] - Recent legislation passed by Congress will allow for Medicare coverage of multi-cancer early detection tests starting in 2028, which the company plans to leverage for its OneTest [5] Product and Technology Advantages - 20/20 BioLabs' OneTest combines established protein tumor markers with machine learning AI, offering advantages over DNA-based tests, including cost-effectiveness and better detection rates for early-stage cancers [5] - The OneTest can be administered using pain-free capillary blood collection methods, making it accessible for use at home, workplaces, or retail locations [5][6]

Core Viewpoint - Hudson Technologies has signed a licensing agreement with Solstice Advanced Materials for the reclamation and resale of R-448A and R-449A refrigerants, which are lower GWP alternatives to higher GWP HFC refrigerants, aligning with regulatory trends in the refrigeration industry [1][2][3]. Group 1: Company Overview - Hudson Technologies is a leading provider of sustainable refrigerant products and services in the HVACR industry, recognized as one of the largest refrigerant reclaimers in the U.S. [4]. - The company has invested significantly in advanced separation technology to recover a variety of refrigerants, restoring them to standards for reuse as certified EMERALD Refrigerants™ [4]. - Hudson's services include refrigerant management, reclamation, and predictive diagnostic services, contributing to energy efficiency and carbon offset projects [4]. Group 2: Licensing Agreement Details - The licensing agreement allows Hudson Technologies to reclaim and resell R-448A and R-449A in the U.S. and Canada, enhancing its market presence in commercial refrigeration [2][3]. - R-448A and R-449A are positioned as popular lower-GWP refrigerant options, creating significant aftermarket service gas demand as legacy refrigerants face regulatory constraints [3]. Group 3: Strategic Implications - The agreement with Solstice Advanced Materials builds on a long-term relationship and supports Hudson's strategic focus on expanding sales and service capabilities with next-generation refrigerants [3].

Core Viewpoint - Jyong Biotech Ltd. is advancing its plant-derived drug MCS-2, which has completed Phase III clinical trials for benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), highlighting its competitive advantages and potential clinical benefits [1][2]. Group 1: Clinical Development - MCS-2 is the only oral botanical new drug globally to complete Phase III clinical trials for BPH, with four trials conducted in the U.S. and Taiwan, including pivotal trials and open-label extensions [2][4]. - The trials involved over 200 urologists across 27 centers in 19 U.S. states and more than 70 urologists in 12 major hospitals in Taiwan, establishing a robust physician network for future commercialization [3][4]. Group 2: Safety and Efficacy - MCS-2 has demonstrated excellent safety across all Phase III trials, with no serious adverse events reported, supporting its long-term use [4]. - The drug has undergone rigorous scientific validation, adhering to FDA guidelines and completing over ten international toxicology studies [4]. Group 3: Intellectual Property - Jyong Biotech holds global patent protection for its core technology, enhancing bioavailability and enabling various formulations, including oral and injectable forms [5]. Group 4: Market Potential - BPH/LUTS affects hundreds of millions of men globally, with current treatments often leading to side effects and drug resistance, creating a significant unmet need for safe, long-term solutions [6][7]. - The aging global population and increasing healthcare demand present substantial growth potential for prostate disease treatment and prevention [7]. Group 5: Company Commitment - Jyong Biotech emphasizes innovation and R&D, adhering to international standards for quality and regulatory compliance, positioning itself for global market entry and partnerships [8][11]. - The company aims to develop first-class innovative drugs to meet health needs and enhance its reputation as a valuable business organization [11].

Core Viewpoint - Norwegian Cruise Line Holdings Ltd. has appointed five new independent members to its Board of Directors and entered into a cooperation agreement with Elliott Investment Management, emphasizing its commitment to board refreshment and shareholder value creation [2][4]. Board Appointments - Effective March 31, 2026, John W. Chidsey has been appointed as Chairman, and Alex Cruz as Lead Independent Director. Current Board members Stella David, David M. Abrams, Harry C. Curtis, and Mary E. Landry will resign, resulting in a Board of nine members, eight of whom are independent [3][4]. - The upcoming 2026 Annual General Meeting will feature directors Zillah Byng-Thorne, Linda P. Jojo, and Alex Cruz [3]. Cooperation Agreement with Elliott - Elliott Investment Management, as the largest investor, sees potential for significant value creation under the new leadership and believes the new Board will help restore investor confidence and improve financial performance [4]. - The cooperation agreement includes customary standstill and voting commitments, reflecting a shared commitment to enhancing performance and long-term value for shareholders [4]. New Board Member Biographies - Alex Cruz brings extensive experience from his tenure as Chairman and CEO of British Airways, focusing on operational transformation and recovery from COVID-19 [8][9]. - Kevin A. Lansberry has nearly four decades of experience in finance and operations, having served as CFO at Disney Experiences [12][14]. - Steve Pagliuca has over three decades in private equity and investment, previously a Managing Partner at Bain Capital [15][17]. - Brian P. MacDonald has significant experience in the automotive and technology sectors, currently serving as CEO of CDK Global [18][20]. - Jonathan Z. Cohen has over three decades in alternative asset management and has held leadership roles in various investment firms [21][23]. Company Overview - Norwegian Cruise Line Holdings Ltd. operates Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, with a fleet of 35 ships and nearly 75,000 berths, offering itineraries to approximately 700 destinations worldwide [24]. - The company plans to add 16 additional ships by 2037, which will increase its fleet capacity by over 43,000 berths [24].

Core Viewpoint - ORIC Pharmaceuticals, Inc. will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) for metastatic castration resistant prostate cancer on March 31, 2026 [1] Group 1: Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments that address mechanisms of therapeutic resistance in cancer [3] - The company's product candidates include rinzimetostat (ORIC-944), an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor for non-small cell lung cancer (NSCLC) [3] - ORIC has offices located in South San Francisco and San Diego, California [3] Group 2: Conference Call Details - A conference call and webcast will take place on March 31, 2026, at 4:30 pm ET to discuss the trial data [1] - Participants can pre-register online to join the conference call and will receive a unique passcode for entry [2] - The webcast will be available for replay for 90 days following the presentation [2]

Core Insights - One and One Green Technologies, a licensed hazardous waste importer and recycler in the Philippines, has launched a new business venture focused on recovering copper-gold ore tailings slag in Luzon to address a supply deficit in the global copper market [1][2][4]. Company Overview - One and One Green Technologies operates as a recycler of non-ferrous metals and industrial materials, transforming electronic waste and scrap metal into high-value products such as copper alloy ingots and aluminum scraps [5]. - The company is strategically positioned to meet the increasing demand for sustainable resource management, with significant permitted annual capacity and advanced processing capabilities [5]. Industry Context - The International Copper Study Group (ICSG) has projected a supply deficit of 150,000 metric tons of copper in 2026, indicating a tightening global copper market [2]. - By 2040, S&P Global anticipates a supply imbalance of 10 million metric tons of copper, driven by factors such as energy transition, electrification, and the expansion of AI data centers [3]. Strategic Initiatives - The company plans to collaborate with small-scale mining companies in the mineral-rich Luzon region to source copper-gold ore tailings slag, which will be processed at its main plant and exported [2][4]. - This integrated approach aims to create a new, high-growth income source while capturing value from both recycled copper and primary tailings slag [3][4].

Core Viewpoint - BranchOut Food Inc. is set to host a conference call on March 31, 2026, to discuss its fourth quarter and full year 2025 financial results, along with a corporate and shareholder update [1][2]. Company Overview - BranchOut Food Inc. is a leading international food technology company that specializes in producing high-quality dehydrated fruit and vegetable-based products using its proprietary GentleDry Technology [5]. - The GentleDry process preserves up to 95% of the original nutrition of fresh produce, ensuring superior quality and taste [5]. - The company holds over 17 patents for its technology, establishing itself as a trusted brand and supplier in the market [5]. Event Details - The conference call will take place on March 31, 2026, at 4:30 PM ET and is expected to last for 60 minutes [6]. - Participants can join the call via a toll-free number or an international line, with specific dial-in information provided [6]. - A replay of the conference call will be available approximately three hours after the live event and will remain accessible until April 28, 2026 [4].

Core Insights - Changan Automobile and CAOA inaugurated a highly automated production line in Anápolis, Brazil, marking a significant advancement in the country's automotive industry and signaling a commitment to high-tech industrialization and green mobility [1][4] Investment and Capacity - The inauguration initiates a new investment cycle of USD 950 million (R$ 5 billion) for 2026-2028, building on a previous investment of USD 570 million (R$ 3 billion) from 2023, bringing total investment in Anápolis to USD 1.52 billion (R$ 8 billion) with an annual production capacity of 90,000 units [4] Engineering and Innovation - The CHANGAN UNI-T was developed through three years of collaboration between 200 Chinese and Brazilian engineers, featuring an advanced 1.5 Turbo GDi BlueCore Flex engine tailored for ethanol-petrol blends [8] - The vehicle underwent extensive testing of 200,000 km across Brazil's diverse climates, ensuring it meets local durability, efficiency, and performance standards, while incorporating localized innovations such as a Portuguese voice control system [9] Strategic Goals - The UNI-T is positioned as a key model in Brazil's reindustrialization plan, supporting the federal government's MOVER program through investments in digital assembly lines and workforce training [11] - Changan plans to expand its product range with hybrid and electrified variants, enhancing local supply chains and R&D, while opening over 60 dealerships in 2026 to strengthen its sales footprint in Brazil [12]